The FDA’s approval of daraxonrasib (Rasonque) on August 26, 2026, for previously treated metastatic pancreatic ductal adenocarcinoma underpins the near-certain market odds. This first-in-class oral RAS(ON) multiselective inhibitor targets the RAS mutations driving over 90% of pancreatic cancers. The pivotal phase 3 RASolute 302 trial showed it nearly doubled median overall survival to 13.2 months versus 6.7 months with chemotherapy, with similar gains in progression-free survival and a manageable safety profile. Breakthrough Therapy, Orphan Drug, and Priority Review designations, plus the Commissioner’s National Priority Voucher program, enabled review 6.5 months ahead of the user-fee deadline. With approval now granted, only an unprecedented post-approval withdrawal could alter the outcome before year-end.